CivaTech Oncology

Focus: CivaTech Oncology is an early-stage biotechnology company specializing in localized radiotherapy solutions for solid tumors, founded in 2023 and headquartered in Morrisville, NC. The company operates as a pre-revenue biotech with a focused portfolio of radiation-based oncology products.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CivaTech Oncology

AI assessmentNot Hiring

No open roles listed right now. Follow CivaTech Oncology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Linear LDR Source

Prostate Cancer

N/A

Clinical Trials (1)

NCT02516709Linear Source Registry for Prostate Cancer

N/A

Help build intelligence for CivaTech Oncology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded (2023) company with a novel localized radiotherapy platform addressing multiple high-mortality cancer types
Diversified pipeline across 7 clinical programs spanning lung, pancreatic, prostate, and sarcoma indications with Phase 4 data in sarcoma
Emerging modality (brachytherapy and radiotherapy devices) represents white space in oncology with less crowded competitive landscape than checkpoint inhibitors

Watch Out For

Zero current job openings and undisclosed funding/employee count suggest early stealth-mode operations with uncertain near-term hiring plans
No revenue-generating products, no published clinical data (0 publications), and majority of pipeline in Phase 1 (4 of 7 programs) creates execution risk and cash runway uncertainty
Company is less than 2 years old with unknown financial backing—typical biotech mortality rate for pre-revenue stage is high

Generated by Claude from CivaTech Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CivaDerm

Basal Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT04480645CivaDerm(TM) Surface Therapy Pilot Study

Phase 1

CivaSheet

Pancreas Cancer

Phase 1

Clinical Trials (1)

NCT03109041Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source

Phase 1